20
Participants
Start Date
August 1, 2025
Primary Completion Date
August 1, 2026
Study Completion Date
August 1, 2027
CAR19BCMA-T cells
"CAR19BCMA-T cells Each subject will be infused with single dose of CD19BCMA-CAR-T cells. A classic 3+3 dose escalation will be employed. The low dose is 1×10\^6 /kg, the medium dose is 2×10\^6 /kg, and the high dose is 3×10\^6 /kg.~Drug: fludarabine and cyclophosphamide Drug: Fludarabine Fludarabine will be given at a dose of 30 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD19BCMA-CAR-T cells. Drug: Cyclophosphamide Cyclophosphamide will be given at a dose of 300 mg"
The Four Medical Center of PLA General Hospital, China, Beijing
The Six Medical Center of PLA General Hospital, China, Beijing
Chinese PLA General Hospital
OTHER